Suchergebnisse - "Nilsson, Monique B"

PubPharm (12)

1

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Patel, S. | Nilsson, M. | Yang, Y. | +14

2

Poziotinib for EGFR exon 20-mutant NSCLC : Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

enthalten in: Cancer cell | 2022

von Elamin, Y. | Robichaux, J. | Carter, B. | +24

CommentIn: Cancer Cell. 2022 Jul 11;40(7):705-708. - PMID 35820394

3

ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC

enthalten in: Cancer cell | 2021

von Le, X. | Nilsson, M. | Robichaux, J. | +1

CommentOn: Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. - PMID 34388377

4

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Negrao, M. | Raymond, V. | Lanman, R. | +19

5

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

enthalten in: Science translational medicine | 2020

von Nilsson, M. | Sun, H. | Robichaux, J. | +21

6

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

enthalten in: Cancer cell | 2019

von Robichaux, J. | Elamin, Y. | Vijayan, R. | +28

ErratumIn: Cancer Cell. 2020 Mar 16;37(3):420. - PMID 32183953

7

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2018

von Le, X. | Puri, S. | Negrao, M. | +21

CommentIn: Clin Cancer Res. 2018 Dec 15;24(24):6112-6114. - PMID 30352903

8

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

enthalten in: Nature medicine | 2018

von Robichaux, J. | Elamin, Y. | Tan, Z. | +21

CommentIn: Nat Rev Clin Oncol. 2018 Jul;15(7):404. - PMID 29743681

9

Stress hormones promote EGFR inhibitor resistance in NSCLC : Implications for combinations with β-blockers

enthalten in: Science translational medicine | 2017

von Nilsson, M. | Sun, H. | Diao, L. | +22

CommentIn: Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S117-S122. - PMID 29782563

10

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2017

von Cascone, T. | Xu, L. | Lin, H. | +22